Table of Contents
There is a chemical in your brain that wants you to go broke.
It does not care about your retirement. It does not care about your risk tolerance or your carefully constructed portfolio. It was designed about 200,000 years ago to help you survive on the savanna, and it has not received a software update since.
Its name is oxytocin. You probably know it as the “love hormone” or the “bonding chemical.” It floods your system when you hug your children, when you fall in love, when your dog looks at you with those ridiculous eyes. It is the neurochemical foundation of trust.
And every charismatic founder on a conference stage is hacking it like a teenager with a WiFi password.
The Biology You Did Not Sign Up For
Here is something that should concern you. When researchers at Claremont Graduate University studied oxytocin and financial decisions, they found that participants who received a nasal spray of synthetic oxytocin were willing to give significantly more money to strangers in trust games. Not because they had better information. Not because the strangers were more trustworthy. Simply because the chemical said so.
Now imagine that instead of a nasal spray, the delivery mechanism is a founder in a black turtleneck telling you he is going to change the world. Same chemical. Different syringe.
This is the part of behavioral finance that rarely gets discussed in polite company. We spend enormous energy analyzing balance sheets and market fundamentals, but almost no time examining the fact that our brains are running ancient software in a modern financial environment. The mismatch is not just inconvenient. It is expensive.
Oxytocin release is not random. It follows predictable triggers. Eye contact. Storytelling. Vulnerability. Shared identity. A founder who masters these triggers, whether consciously or by natural talent, is essentially performing biochemistry on a live audience. The audience then calls this feeling “conviction” and writes checks.
The Storyteller Problem
Human beings are not wired to evaluate business models. We are wired to evaluate stories.
This is not a metaphor. Neuroscience research has consistently shown that narrative activates brain regions that raw data simply cannot reach. When someone tells you a story, your brain synchronizes with theirs. Mirror neurons fire. You experience their emotions as if they were your own. A well told story about disrupting an industry does more to your prefrontal cortex than a spreadsheet full of unit economics ever could.
This is why Elizabeth Holmes raised nearly $700 million for technology that did not work. This is why Adam Neumann convinced sophisticated investors that a commercial real estate company was actually a tech platform worth $47 billion. The stories were magnificent. The numbers were, to put it gently, less so.
But here is the part that should keep you up at night. The investors who funded these ventures were not amateurs. They were partners at some of the most respected firms in the world. People who had spent decades evaluating companies. People with teams of analysts and access to every financial tool imaginable.
They got the same oxytocin hit as everyone else. The molecule does not check your LinkedIn credentials before it floods your synaptic clefts.
Why Smart Money Is Not Immune
There is a comforting myth in finance that sophistication protects you from cognitive bias. That institutional investors, with their due diligence processes and investment committees, somehow transcend the wetware limitations that plague retail investors.
The evidence suggests otherwise.
SoftBank’s Vision Fund, managed by one of the most experienced investors in technology, poured billions into companies helmed by charismatic founders. The results were, in several notable cases, catastrophic. But Masayoshi Son described his investment process in terms that would make a behavioral scientist wince. He talked about “feeling the force” of entrepreneurs. About looking into their eyes and sensing their destiny.
That is oxytocin talking. It just has a $100 billion microphone.
The counterintuitive truth is that expertise can actually make you more vulnerable to charisma, not less. When you have a long track record of success, you develop confidence in your instincts. Your gut has been right before. So when your gut tells you this founder is the real deal, you trust it. You interpret a neurochemical reaction as pattern recognition. And pattern recognition is the thing that made you successful in the first place.
This is how the trap works. It does not feel like a trap. It feels like insight.
The Halo That Pays Dividends (Until It Does Not)
Psychologists have a name for what happens once oxytocin establishes initial trust. It is called the halo effect, and in founder worship it operates like compound interest on a bad loan.
Once you trust someone, your brain begins to reinterpret everything they do through a favorable lens. The founder is not reckless. He is bold. He is not evasive about financials. He is focused on the vision. The company is not burning cash. It is investing in growth.
Each positive reinterpretation strengthens the trust, which triggers more oxytocin, which makes the next reinterpretation even more generous. It is a feedback loop with no natural circuit breaker. And it explains one of the most baffling patterns in financial disasters: why the warning signs were always visible in hindsight but invisible in real time.
Because they were visible. People just could not see them through the halo.
The Tribe Tax
Oxytocin does something else that matters enormously for your portfolio. It does not just bond you to a person. It bonds you to a group.
When you invest in a charismatic founder, you do not just buy equity. You join a tribe. And tribes have rules, the most important of which is this: you do not question the leader. Not publicly. Not seriously.
This is why the comment sections of certain investment communities read like the minutes of a support group. Skepticism is treated as betrayal. Due diligence is reframed as a lack of faith. And the people who raise legitimate concerns are not engaged with. They are expelled.
The biological logic is straightforward. On the savanna, group cohesion was survival. Questioning the leader could fracture the group. Oxytocin reinforced loyalty by making dissent feel physically uncomfortable. That slight nausea you feel when you consider selling a stock that your entire online community is passionate about? That is not your conscience. That is 200,000 years of tribal programming telling you that leaving the group means getting eaten by a lion.
There are no lions on the NASDAQ. But your amygdala has not been informed.
The Vulnerability Weapon
Of all the oxytocin triggers that charismatic founders deploy, vulnerability might be the most potent and the least understood.
When a founder shares a personal struggle, a childhood hardship, a moment of doubt, a failure they overcame, your brain interprets this as a signal of trustworthiness. The logic, from an evolutionary perspective, is sound. Someone who reveals weakness to you is unlikely to be a threat. They are signaling that they trust you, which makes you trust them in return.
In a genuine relationship, this is beautiful. In a capital allocation decision, it is a disaster.
Because vulnerability can be performed. And performed vulnerability is almost indistinguishable from the real thing. Your oxytocin system cannot tell the difference between a founder who genuinely cares about their mission and a founder who has learned that a well timed tear during a pitch meeting adds a zero to the valuation.
This does not mean all founder vulnerability is fake. Many founders are deeply sincere people who have genuinely struggled. The problem is that sincerity and competence are different things entirely. A founder can be completely honest about their passion to cure a disease and completely incapable of running the company that is supposed to do it. Your brain, flooded with trust hormones, will conflate the two every single time.
The Sobriety Test for Your Portfolio
So what do you actually do with this information? You cannot remove oxytocin from your brain. You cannot stop responding to charisma. You are a mammal. These are features, not bugs.
But you can build what behavioral economists call “choice architecture” around your investments. Think of it as a breathalyzer for your portfolio.
The first step is the simplest and the hardest. Separate the founder from the financials. Physically. Read the financial statements before you watch the keynote. Form your opinion about the business before you form your opinion about the person running it. This sounds obvious. Almost nobody does it.
The second step involves time. Oxytocin has a half life. The rush you feel after watching an inspiring presentation does not last forever. If you institute a mandatory waiting period between emotional exposure to a founder and any investment decision, you give your neurochemistry time to return to baseline. Seventy two hours is a reasonable starting point. If the investment still looks good when the chemicals have worn off, it might actually be good.
The third step is adversarial by design. Before making any significant investment in a founder led company, actively seek out the most compelling bear case. Not to be a pessimist. But because your oxytocin soaked brain has already built the bull case for you, automatically, without your permission. You need a counterweight.
The fourth step, and this one requires genuine self awareness, is to notice when you are defending an investment with emotional language. When you catch yourself saying “I believe in this founder” instead of “the unit economics support this valuation,” that is a signal. Belief is for temples. Finance is for spreadsheets. The overlap between the two is where money goes to die.
The Paradox Nobody Wants to Hear
Here is where things get uncomfortable. Charismatic founders sometimes build incredible companies.
Steve Jobs was famously charismatic and famously difficult and built one of the most valuable companies in human history. Elon Musk generates enough oxytocin at a product launch to bond a small nation, and his companies have accomplished things that seemed genuinely impossible.
The existence of these examples makes the oxytocin trap more dangerous, not less. Because they give your brain exactly what it needs to justify the next charismatic founder who comes along. “Sure, most of them fail,” your oxytocin whispers, “but what if this one is the next Jobs?”
This is survivorship bias wearing a turtleneck. For every charismatic founder who delivers, dozens flame out. You do not hear about them because failure is quiet and success is loud. Your brain remembers the hits and forgets the misses, and oxytocin ensures that each new charismatic encounter feels like a hit in progress.
The honest answer is that charisma is uncorrelated with competence. Some great founders are charismatic. Some terrible founders are charismatic. Charisma tells you about the founder’s ability to trigger your neurochemistry. It tells you nothing about their ability to build a business.
Trust Your Doubt
We live in a culture that celebrates conviction and pathologizes skepticism. Investors who express doubt are called “haters.” Analysts who question valuations are accused of “not getting it.” The entire infrastructure of founder worship is designed to make critical thinking feel like a personality flaw.
But doubt is not a flaw. It is a feature. It is the one cognitive tool that oxytocin cannot easily override, because doubt lives in the prefrontal cortex, the part of your brain that evolved specifically to question the impulses generated by older systems.
Your prefrontal cortex is the newest part of your brain. It is also the quietest. It does not generate warm feelings of trust or rushes of excitement. It generates questions. Annoying, uncomfortable, buzzkill questions like “what are the actual margins?” and “has anyone independently verified this technology?”
Listen to it. It is trying to save you money.
The oxytocin trap is not a conspiracy. No founder wakes up thinking “today I will biochemically manipulate investors.” It is a systems problem. Evolution built us to trust charismatic leaders. Modern finance puts charismatic leaders in front of us and asks for our money. The collision between these two facts is entirely predictable, and entirely avoidable, if you know what is happening inside your own skull.
Your brain wants to trust. Your portfolio needs you to verify. The tension between those two things is not a problem to solve. It is a discipline to practice.
Every single day you invest.
